Navigation Links
Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
Date:5/3/2012

MALVERN, Pa., May 3, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2012 on Thursday, May 10, 2012 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the first quarter 2012.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 10 a.m. ET on Thursday, May 10, 2012.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Thursday, May 10, 2012.  A question and answer session will follow the presentation. 

(Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

Mr. Adrian Adams, Chief Executive Officer and President, will host the conference call.Conference call details:Date:

Thursday, May 10, 2012Time:

10:00 a.m. ETDial-in (U.S.):

866-356-4281Dial-in (International):

617-597-5395Web cast:

http://www.auxilium.comPasscode:

AUXILIUMTo access an audio replay of the call:Access number (U.S.):

888-286-8010 Access number (International):

617-801-6888Replay Passcode #:

50696959About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.  Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, in phase IIa of development for the treatment of Frozen Shoulder syndrome (Adhesive Capsulitis) and is in phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the first quarter 2012 results; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite.  Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.  A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011, which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com
William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
3. Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference
4. Auxilium Pharmaceuticals to Present at the 2012 Cowen Healthcare Conference
5. BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
6. Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico
7. Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
9. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
11. Auxilium Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 2016 , ... Afrimesure specializes in providing clients with ideal ... and HVAC facilities. Their knowledgeable staff also takes care of the installation, IQ/OQ/PQ ... offers a variety of MadgeTech systems available for sterilization and temperature monitoring, including ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, delivering ... and Prescription Drug survey , an employee benefits survey measuring how ... in December 2015, indicates that employers are turning to consumer directed health care ...
(Date:5/25/2016)... ... May 25, 2016 , ... For more than fifty years, we've suffered whiplash as each ... diets to conform to the latest nutritional advice – advice that was supposed to keep ... than 2 in 3 American adults are considered to be overweight and more than 1 ...
(Date:5/25/2016)... ... May 25, 2016 , ... BeniComp Insurance Company, a leading ... their clients' employee participation for their wellness initiatives. BeniComp clients experience nearly ... health plan with outcome-based deductible incentives. As a result, BeniComp clients have been ...
(Date:5/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... as the Medical Director of its new DeSoto facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
Breaking Medicine News(10 mins):